Cardiovascular Partnering Terms and Agreements

Date: August 1, 2014
Pages: 493
Price:
US$ 2,995.00
License [?]:
Publisher: CurrentPartnering
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), CD-ROM Mail Delivery, E-mail Delivery (Word)
ID: CDF0DA84BB5EN
Leaflet:

Download PDF Leaflet

Cardiovascular Partnering Terms and Agreements
The Cardiovascular Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the cardiovascular partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in cardiovascular partnering deals
  • Average deal terms for headline, upfront and royalty by stage of development
  • Cardiovascular partnering agreement structure
  • Cardiovascular partnering contract documents
  • Top cardiovascular deals by value
  • Most active cardiovascular dealmakers
The Cardiovascular Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the cardiovascular partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter cardiovascular partnering deals. The majority of deals are discoveryor development stage whereby the licensee obtains a right or an option right to license the licensors cardiovascular technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 2,000 links to online copies of actual cardiovascular deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cardiovascular dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cardiovascular deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of cardiovascular deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of cardiovascular partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), technology type and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cardiovascular partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cardiovascular technologies and products.

Report scope

Cardiovascular Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to cardiovascular trends and structure of deals entered into by leading companies worldwide.

Cardiovascular Partnering Terms and Agreements includes:
  • Trends in cardiovascular dealmaking in the biopharma industry since 2009
  • Analysis of cardiovascular deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life cardiovascular deals
  • Access to over 2,000 cardiovascular deal records
  • The leading cardiovascular deals by value since 2009
  • Most active cardiovascular dealmakers since 2009
  • The leading cardiovascular partnering resources
In Cardiovascular Partnering Terms and Agreements, the available contracts are listed by:
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cardiovascular Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 2,000 cardiovascular deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN CARDIOVASCULAR DEALMAKING

2.1. Introduction
2.2. Cardiovascular partnering over the years
2.3. Bigpharma cardiovascular dealmaking activity
2.4. Bigpharma not active in cardiovascular
2.5. Cardiovascular partnering by deal type
2.6. Cardiovascular partnering by industry sector
2.7. Cardiovascular partnering by stage of development
2.8. Cardiovascular partnering by technology type
2.9. Cardiovascular partnering by cardiovascular indication
2.10. Average deal terms for cardiovascular
  2.10.1 Cardiovascular headline values
  2.10.2 Cardiovasular upfront payments
  2.10.3 Cardiovascular milestone payments
  2.10.4 Cardiovascular royalty rates

CHAPTER 3 – LEADING CARDIOVASCULAR DEALS

3.1. Introduction
3.2. Top cardiovascular deals by value
3.3. Top cardiovascular deals involving bigpharma

CHAPTER 4 – BIGPHARMA CARDIOVASCULAR DEALS

4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma cardiovascular partnering company profiles
Abbott
Actavis
Actelion
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
Eisai
Eli Lilly
Forest Laboratories
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Otsuka
Pfizer
Roche
Sanofi
Servier
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

CHAPTER 5 – CARDIOVASCULAR PARTNERING CONTRACTS DIRECTORY

5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing - OEM
Marketing
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Termination
Warranty
5.3. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
5.4. By technology type
Assays
Biodefense
Bioinformatics
Biological compounds
Biomarkers
Blood products
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Equipment
Facilities
Gene therapy
Genomics
Imaging
Implant
Natural product
Oligonucleotide
Orphan drug
Packaging
Peptides
Personalised medicine
Processes
Proteomics
Recombinant DNA
Regenerative medicine
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Stem cells

CHAPTER 6 – CARDIOVASCULAR DEALMAKING BY INDICATION

6.1. Introduction
6.2. Deals by therapeutic indication
Cardiovascular
Abdominal aortic aneurysm
Angina
Arrhythmia
Atrial fibrillation
Long QT syndrome
Supraventricular Tachycardia
Atherosclerosis
Cardiogenic shock
Cardiomyopathy (heart muscle disease)
Chest pain
Congenital heart disease
Congestive heart failure
Coronary artery disease
Ductus arteriosus
Hypercholesterolemia
Hypertension
Intermittent claudication
Ischemic heart disease
Limb ischemia
Myocardial Infarction
Oedema (excess fluid)
Peripheral arterial disease
Thrombus (blood clot)
Restenosis
Varicose veins

CHAPTER 7 – PARTNERING RESOURCE CENTER

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

APPENDICES

APPENDIX 1 – Directory of cardiovascular deals by company A-Z 2009-2014
APPENDIX 2 – Directory of cardiovascular deals by deal type 2009-2014
APPENDIX 3 – Directory of cardiovascular deals by stage of development 2009-2014
APPENDIX 4 – Directory of cardiovascular deals by technology type 2009-2014
APPENDIX 5 – Deal type definitions

ABOUT WILDWOOD VENTURES

Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

TABLE OF FIGURES

Figure 1: Cardiovascular partnering since 2009
Figure 2: Bigpharma – top 50 – cardiovascular deals 2009 to 2012
Figure 3: Bigpharma cardiovascular deal frequency – 2009 to 2012
Figure 4: Inactive bigpharma in cardiovascular 2009-2014
Figure 5: Cardiovascular partnering by deal type since 2009
Figure 6: Cardiovascular partnering by industry sector since 2009
Figure 7: Cardiovascular partnering by stage of development since 2009
Figure 8: Cardiovascular partnering by technology type since 2009
Figure 9: Cardiovascular partnering by cardiovascular target since 2009
Figure 10: Cardiovascular deals with a headline value
Figure 11: Cardiovasular deal headline value distribution, US$million – discovery stage
Figure 12: Cardiovasular deal headline value distribution, US$million – preclinical stage
Figure 13: Cardiovasular deal headline value distribution, US$million – phase I stage
Figure 14: Cardiovasular deal headline value distribution, US$million – phase II stage
Figure 15: Cardiovasular deal headline value distribution, US$million – phase III stage
Figure 16: Cardiovasular deal headline value distribution, US$million – regulatory stage
Figure 17: Cardiovasular deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2009-2014
Figure 19 Cardiovasular deals with upfront payment values
Figure 20: Cardiovascular deal upfront payment distribution, US$million – discovery stage
Figure 21: Cardiovascular deal upfront payment distribution, US$million – preclinical stage
Figure 22: Cardiovascular deal upfront payment distribution, US$million – phase I stage
Figure 23: Cardiovascular deal upfront payment distribution, US$million – phase II stage
Figure 24: Cardiovascular deal upfront payment distribution, US$million – phase III stage
Figure 25: Cardiovascular deal upfront payment distribution, US$million – regulatory stage
Figure 26: Cardiovascular deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2009-2014
Figure 28: Cardiovascular deals with milestone payments
Figure 29: Cardiovascular deal milestone distribution, US$million – discovery stage
Figure 30: Cardiovascular deal milestone distribution, US$million – preclinical stage
Figure 31: Cardiovascular deal milestone distribution, US$million – phase I stage
Figure 32: Cardiovascular deal milestone distribution, US$million – phase II stage
Figure 33: Cardiovascular deal milestone distribution, US$million – phase III stage
Figure 34: Cardiovascular deal milestone distribution, US$million – regulatory stage
Figure 35: Cardiovascular deal milestone distribution, US$million – marketed stage
Figure 36: Cardiovascular deals with royalty rates, %
Figure 37: Cardiovascular deal royalty rate distribution, US$million – discovery stage
Figure 38: Cardiovascular deal royalty rate distribution, US$million – preclinical stage
Figure 39: Cardiovascular deal royalty rate distribution, US$million – phase I stage
Figure 40: Cardiovascular deal royalty rate distribution, US$million – phase II stage
Figure 41: Cardiovascular deal royalty rate distribution, US$million – phase III stage
Figure 42: Cardiovascular deal royalty rate distribution, US$million – regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2009-2014
Figure 45: Top cardiovascular deals by value since 2009
Figure 46: Top cardiovascular deals signed by bigpharma value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Companion Diagnostics Partnering Terms & Agreements US$ 1,995.00 Apr, 2014 · 378 pages
Pharmacogenomics Partnering Terms and Agreements US$ 1,995.00 Oct, 2013 · 228 pages
Bioinformatics Partnering Terms and Agreements US$ 2,995.00 Sep, 2013 · 1268 pages
Discovery Stage Partnering Terms and Agreements US$ 3,295.00 Feb, 2014 · 4436 pages
Biomarker Partnering Terms and Agreements US$ 2,995.00 Apr, 2014 · 998 pages

Ask Your Question

Cardiovascular Partnering Terms and Agreements
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: